- In January 2025, Soleno Therapeutics announced positive Phase 3 results for DCCR (diazoxide choline controlled-release), its lead candidate for the treatment of hyperphagia and other symptoms in Prader-Willi Syndrome.
- In October 2024, Levo Therapeutics received orphan drug designation from the U.S. FDA for LV-101 (intranasal carbetocin), designed to improve social and behavioral symptoms associated with PWS.
